<code id='533710B8DC'></code><style id='533710B8DC'></style>
    • <acronym id='533710B8DC'></acronym>
      <center id='533710B8DC'><center id='533710B8DC'><tfoot id='533710B8DC'></tfoot></center><abbr id='533710B8DC'><dir id='533710B8DC'><tfoot id='533710B8DC'></tfoot><noframes id='533710B8DC'>

    • <optgroup id='533710B8DC'><strike id='533710B8DC'><sup id='533710B8DC'></sup></strike><code id='533710B8DC'></code></optgroup>
        1. <b id='533710B8DC'><label id='533710B8DC'><select id='533710B8DC'><dt id='533710B8DC'><span id='533710B8DC'></span></dt></select></label></b><u id='533710B8DC'></u>
          <i id='533710B8DC'><strike id='533710B8DC'><tt id='533710B8DC'><pre id='533710B8DC'></pre></tt></strike></i>

          Home / entertainment / focus

          focus


          focus

          author:comprehensive    Page View:57971
          Hiram Secrist (left), who has Duchenne muscular dystrophy, with his mother, Kristen Secrist (center), and his grandmother, Terrie Jordan. Courtesy Secrist family

          In mid-July, Kristen Secrist hopped on a call with her 5-year-old son’s doctor, who had urgent news: The first gene therapy had been approved for Duchenne muscular dystrophy. Her son, Hiram, would be a perfect candidate — if, she added, they could get him dosed in time.

          The treatment was approved only for 4- and 5-year-olds. Hiram turned 6 in three weeks. 

          advertisement

          “Oh, crap,” Secrist said to herself.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In